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Background: Cystic Fibrosis (CF) genotypes in South Asians are variable with a decreased incidence of Delta F508 and an increased incidence of
novel mutations. The objective of this study is to provide clinical evidence that V456A, a novel mutation in South Asian Cystic Fibrosis patients,
can cause signiﬁcant lung disease.
Methods: We extracted clinical data from a retrospective chart review of 2 CF patients of South Asian descent.
Results: Patient 1, a 10 year and 11 month old Pakistani female at her initial clinic visit, required multiple hospitalizations for bronchiectasis and
pulmonary infections. She was pancreatic sufﬁcient but had slow weight gain. Genetic testing revealed that she is homozygous for the CFTR
V456A mutation. Patient 2, an Indian female diagnosed with CF on newborn screening, is compound heterozygous for V456A/R709X. She
had slow weight gain with BMI ranging from 12.9 to 13.4 kg/m2 from 3 to 5 years of age and was 14.2 kg/m2 at 6 years of age. At 6 years of
age, pulmonary function tests revealed mild lung disease with FVC of 71%, FEV1 of 75%, FEF25–75 of 119%, and FEV1/FVC of 86% predicted.
Sputum cultures were intermittently positive for Staphylococcus aureus and Haemophilus influenza.
Conclusions: We provide evidence that V456A can cause signiﬁcant pulmonary disease in South Asian Cystic Fibrosis patients.
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Cystic Fibrosis (CF) is a genetic disease with autosomal reces-
sive inheritance. Significant morbidity and mortality are due to
lung disease, pancreatic insufficiency and sinusitis. CF is com-
mon in the Caucasian population with an incidence of 1:2000
to 1:3500 [2]. CF is not a common diagnosis in South Asians,
with an incidence of 1:9200 to 1:56,600 reported in children of
South Asian descent resident in the United Kingdom, the United
States, and Canada [3–5].☆ Presented in part at 24th National Cystic Fibrosis Conference, October
2010, Baltimore, MD [1].
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Delta F 508 is the most common CF causing mutation in the
world with an incidence of 66% [6]. The genotype of CF in
South Asians includes Delta F508 but this mutation constitutes
only 40–50% of cases and there is an increased incidence of
novel mutations [7–9]. Here we present the clinical course of
2 patients with one such novel mutation (V456A), who have
been diagnosed with CF pulmonary disease.2. Methods
The data were obtained from a retrospective chart review of
2 patients of South Asian descent. This retrospective chart re-
view was approved by the appropriate Institutional Review
Board. Data from the following analyses are presented along
with other relevant clinical findings:
Table 1
Clinical course of patient 1 from initial clinic visit.
Location Time BMI
(kg/m2)
FVC FEV1 FEF25–75 FEV1/FVC Sputum
cultures
Clinic Initial 16.1 31 32 33 97 H.flu
Hospital 2 wks 16.1 44 37 31 81 H.flu
Clinic 4 wks 16.6 43 36 29 79 –
Hospital 6 wks 16.1 – – – – H.flu
Hospital 8 wks 16.1 38 33 24 78 PSA
Diagnosis of CF at 11 years 2 months and initiation of pulmonary treatments
Hospital 10 mos 20 43 34 22 73 NRF
Clinic 23 mos 22.3 65 50 33 73 PSA
FVC, Forced vital capacity; FEV1, Forced expiratory volume in one second;
FEF25–75, Forced expiratory flow between 25 and 75% of FVC; and FEV1/
FVC ratio are reported as percent predicted. Sputum cultures showed H.flu,
Haemophilus influenza; PSA, Pseudomonas aeruginosa; or NRF, Normal re-
spiratory flora.
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Spirometry was performed during clinic visits using
methods based on American Thoracic Society guidelines [10].
The variables measured were Forced Vital Capacity (FVC),
Forced Expired Volume during the first second of a forced ex-
piration (FEV1), Forced Expired Flow between 25 and 75% of
the volume expired during the forced maneuver (FEF25-75)
and FEV1/FVC ratio. Data for the best of three measurements
are reported as percent predicted for height, age, and gender.
2.2. Sweat chloride testing
Thismeasurement was obtained using standard techniques with
analysis by quantitative Pilocarpine ionotophoresis in the clinical
laboratory at Robert Wood Johnson University Hospital, New
Brunswick, NJ which is approved by CLIA (Clinical Laboratory
Improvement Amendments) and has been reviewed by the Cystic
Fibrosis Foundation for accreditation. Samples from each arm
were obtained. A sweat chloride concentration of ≥60 meq/L is
considered diagnostic for CF, a concentration between 40 and
59 meq/L is considered an intermediate value and may be associ-
ated with a possible diagnosis of CF, and a concentration of
≤39 meq/L is considered unlikely to support a diagnosis of CF.
2.3. Genetic testing
Blood samples were obtained by routine venipuncture. They
were processed by ARUP Laboratories, Utah, USA for patient
1 and by Ambry Genetics, California, USA for patient 2.
Both patients had full sequencing of the CFTR gene and analy-
sis for deletions and duplications.
2.4. Microbiology
Sputum samples or a bronchoalveolar lavage sample (patient 1
only) were obtained from the patients and processed in the labora-
tory at Robert Wood Johnson University Hospital for the presence
of common CF bacterial, fungal and mycobacterium pathogens.
2.5. Fecal elastase
Stool samples were processed by enzyme linked immuno-
sorbent assay. Values greater than 200 μg/g are considered
normal, between 100 and 200 μg/g reflect moderate to mild




A 10 year and 11 month old female of Pakistani descent
with consanguineous parents was first seen in our pulmonary
clinic in September 2009 with a history of longstanding pulmo-
nary symptoms. Her clinical course from that initial visit is pre-
sented in Table 1 and detailed below. At initial evaluation,pulmonary function measurements were abnormal with a posi-
tive sputum culture for Haemophilus influenza and she was
started on an oral antibiotic.
Two weeks later she returned to clinic because of persistent
cough. A chest CT showed multiple areas of atelectasis and
bronchiectasis (Fig. 1). She was admitted to hospital and
given IV Ampicillin Sulbactam. A sweat test was negative in
both arms (29/33 meq/L). After one week of IV antibiotics in
hospital along with chest physiotherapy four times a day, a
follow-up chest X-ray showed resolution of infiltrates. She
was discharged home on IV antibiotics. Pulmonary function
measurement at a follow-up clinic visit showed no improve-
ment. IV antibiotics were continued for 3 wks total.
Six weeks after the initial clinic visit, she presented to the emer-
gency room with fever, hypoxia and increased work of breathing.
A chest X-ray showed bibasilar infiltrates and a small right pleural
effusion. The patient was hospitalized for recurrent pneumonia
and was given Ampicillin Sulbactam and Azithromycin. Bron-
choscopy was recommended at that time but was refused by the
family. A Sputum culture was positive forH. influenza. An immu-
nological work-up was normal, including negative findings for
HIV and tuberculosis. A milk scan showed reflux into the proxi-
mal esophagus. She was started on a proton pump inhibitor and
outpatient GI follow-up was recommended. Hypoxia and fever
resolved within 24 h of admission and she was discharged
home on Amoxicillin–Clavulanic Acid.
Eight weeks after her initial clinic visit, she was again admit-
ted to hospital for respiratory distress and hypoxia (arterial ox-
ygen saturation 77% on room air). Immunological evaluation
for recurrent pneumonia was normal. Sputum culture was pos-
itive for Pseudomonas aeruginosa. A repeat sweat test was in-
termediate at 40 meq/L in one arm and negative at 39 meq/L in
the other arm. Bronchoscopy with lavage and biopsy showed dif-
fuse mucoid secretions and normal ciliary architecture. CT of si-
nuses showed pan sinus disease. The patient was treated with
Piperacillin–Tazobactam and Tobramycin Sulfate intravenously
and received chest physiotherapy four times daily for bronchiec-
tasis. Her fecal elastase was normal at 379 μg/dL. CF genetic
analysis revealed that the patient was homozygous for V456A.
Fig. 1. CT scan of chest for patient 1 showing bronchiectasis and mucous plug-
ging in right middle lobe and lingula with significant volume loss in the lingula.
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2 months at which time treatment with aggressive chest physio-
therapy and mucolytics was administered twice daily as is stan-
dard practice in our CF center (Table 1). She was again
admitted to hospital 10 months after initial presentation for pul-
monary exacerbation requiring 2 weeks of IV antibiotic therapy.
On her subsequent clinic visit, her sputum culture was posi-
tive for P. aeruginosa. Her lung function had improved from
severe to moderate obstructive lung disease and her BMI has
increased significantly (Table 1).3.2. Patient 2
A female of Indian descent was diagnosed through positive
newborn screen (elevated immunoreactive trypsinogen). At one
month of age, sweat chlorides were 50 and 51 meq/L and at
22 months of age were similar at 50 and 52 meq/L. Subsequent
genetic analysis showed that she was compound heterozygous
for V456A and R709X. She continued to present in clinic with
difficulty gaining weight. Her BMI in kg/m2 was 12.9, 13.4,
13.2, at 3, 4, and 5 years of age respectively, with all of these
values being below the 3rd percentile for age and gender. At
6 years of age, BMI was 13.9, at the 12th percentile. Fecal elas-
tase was normal at 345 μg/dL indicating normal pancreatic func-
tion. Her sputum cultures were intermittently positive for
Staphylococcus aureus and at 4 years of age were also positive
for H. influenza. Her pulmonary function testing at 6 years of
age showed mild lung disease with FVC of 71%, FEV1 of 75%,
FEF25–75 of 119%, and FEV1/FVC of 86% predicted. A CT
scan of the chest showed peribronchial thickening. She subse-
quently relocated to a different center for follow-up care.4. Discussion
We present the clinical courses of two females of South Asian
descent, one homozygous and one compound heterozygous for
the V456A mutation. Patient 1 had normal or near normal
sweat chloride levels and Patient 2 had levels on two occasionsof approximately 51 meq/L. Neither patient had other common
known CF causing mutations.
Both of our patients with the V456A genotype have low
BMI's with normal pancreatic function and lung disease associ-
ated with low FEV1, FVC and FEV1/FVC, phenotypical find-
ings consistent with previous literature. Mei-Zahav et al. [5]
have described an increased incidence of poor weight gain in
South Asian CF patients, despite pancreatic sufficiency, and de-
creased survival into adulthood. McCormick et al. [11], have
described that lung disease in Asian patients is severe with
worse FEV1 and FVC when compared to Caucasian patients
who are homozygous to the delta F 508 genotype.
Patient 1 presented to clinic with respiratory complaints
alone. Lai et al. [12] have shown that females were diagnosed
at significantly older age than males especially when presenting
with respiratory complaints alone. Our patient 1 was diagnosed
at 11 years and 2 months of age and late diagnosis could have
contributed to her severe lung disease and bacterial coloniza-
tion. However patient 2 was diagnosed early in life but still ex-
hibits lung disease and bacterial colonization.
The genetic spectrum of CF in South Asians includes in-
creased incidence of novel mutations with delta F508 constitut-
ing only 40–50% of cases [5] compared to 66% in the
worldwide CF population [6]. Mutation detection rate in
South Asians is also lower (50% [8]) when compared to 77%
in Caucasians [13] and many South Asian CF patients have
undetected mutations [11].
V456A is a mutation on exon 9 of CFTR resulting in T to C
substitution at codon 456. This changes a valine to an alanine
within exon 9 of CFTR [6]. It was initially described as a poly-
morphism [6]. Subsequently it was suggested to be a mild dis-
ease causing mutation in adults with bronchiectasis and a new
diagnosis of CF when heterozygous with delta F508 [14] and
in females with delayed diagnosis of CF with mild disease
[15] when heterozygous with R709X. It has also been associat-
ed with congenital bilateral absence of vas deferens [6].
V456A is not a common genotype with only 2.4% of 78
South Asian patients exhibiting the V456A/R709X genotype
in the genotyped UK population [16]. Danziger et al. [17] sug-
gested that V456A is a disease causing mutation based on pa-
thology in 4 heterozygous patients with this mutation but 2 of
these patients had delta F508 mutations, one was heterozygous
for R709X, and the other heterozygous for an unidentified mu-
tation. Ambry Genetics and ARUP Laboratories (personal com-
munications) have identified only 3 homozygous patients with
V456A and 8 heterozygous patients with this mutation, includ-
ing our 2 patients described here. Thus it is impossible to con-
clude with certainty that V456A is a disease causing mutation
until further investigations confirm this suggestion using the
criteria recommended in the Cystic Fibrosis Foundation con-
sensus report [18].
We conclude that these cases provide clinical evidence that
V456A is not just a mild polymorphism but a CF disease caus-
ing mutation in South Asians. In patients homozygous for this
mutation, severe pulmonary disease may be present. Formal
proof that V456A is a CF disease causing mutation requires fur-
ther investigation. However, our findings suggest that V456A
315L. Uppaluri et al. / Journal of Cystic Fibrosis 11 (2012) 312–315should be included in the genetic diagnosis of CF in the South
Asian population.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
doi:10.1016/j.jcf.2012.02.001.
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